Chinese API Maker Huahai Leaps Into IO Via Korean Startup
A frenzy for innovation has more Chinese companies armed with cash shopping for new assets. Huahai is the latest to jump onboard the increasingly competitive immuno-oncology field.
You may also be interested in...
Immuno-oncology deals and R&D by South Korean companies are picking up speed as they are put more focus on the hot sector in line with global trends.
Bilateral ties between South Korea and China may have slumped to a new low, but that doesn’t seem to have deterred deals between firms in the two nations in the biotech space. Scrip takes a closer look at the deal-making flow and whether it is sustainable.
Although established only last year, Eutilex is rapidly making its way in the immuno-oncology space. After closing one of the biggest ever Series A funding rounds by a South Korean bioventure, its CEO talks to Scrip about next steps and the priorities for next year.